NASDAQ:BSTC - BioSpecifics Technologies Stock Price, News & Analysis

$58.17
-0.16 (-0.27 %)
(As of 09/18/2019 06:00 AM ET)
Today's Range
$56.94
Now: $58.17
$58.62
50-Day Range
$53.39
MA: $56.76
$59.75
52-Week Range
$52.03
Now: $58.17
$73.31
Volume33,663 shs
Average Volume45,201 shs
Market Capitalization$426.39 million
P/E Ratio19.43
Dividend YieldN/A
Beta1.17
BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX or Xiapex brands. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:BSTC
CUSIP09093110
Phone516-593-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$32.96 million
Cash Flow$3.0827 per share
Book Value$13.41 per share

Profitability

Net Income$20.05 million

Miscellaneous

Employees6
Market Cap$426.39 million
Next Earnings Date11/8/2019 (Estimated)
OptionableNot Optionable

Receive BSTC News and Ratings via Email

Sign-up to receive the latest news and ratings for BSTC and its competitors with MarketBeat's FREE daily newsletter.


BioSpecifics Technologies (NASDAQ:BSTC) Frequently Asked Questions

What is BioSpecifics Technologies' stock symbol?

BioSpecifics Technologies trades on the NASDAQ under the ticker symbol "BSTC."

How were BioSpecifics Technologies' earnings last quarter?

BioSpecifics Technologies Corp. (NASDAQ:BSTC) issued its earnings results on Friday, August, 9th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.72 by $0.15. The biopharmaceutical company earned $8.85 million during the quarter, compared to analysts' expectations of $8.98 million. BioSpecifics Technologies had a return on equity of 21.97% and a net margin of 63.06%. View BioSpecifics Technologies' Earnings History.

When is BioSpecifics Technologies' next earnings date?

BioSpecifics Technologies is scheduled to release their next quarterly earnings announcement on Friday, November 8th 2019. View Earnings Estimates for BioSpecifics Technologies.

What price target have analysts set for BSTC?

1 brokers have issued 1 year price objectives for BioSpecifics Technologies' shares. Their predictions range from $90.00 to $90.00. On average, they anticipate BioSpecifics Technologies' share price to reach $90.00 in the next year. This suggests a possible upside of 54.7% from the stock's current price. View Analyst Price Targets for BioSpecifics Technologies.

What is the consensus analysts' recommendation for BioSpecifics Technologies?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioSpecifics Technologies in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioSpecifics Technologies.

Has BioSpecifics Technologies been receiving favorable news coverage?

News headlines about BSTC stock have trended negative this week, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. BioSpecifics Technologies earned a news impact score of -2.9 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for BioSpecifics Technologies.

Are investors shorting BioSpecifics Technologies?

BioSpecifics Technologies saw a increase in short interest in August. As of August 31st, there was short interest totalling 257,700 shares, an increase of 7.9% from the July 31st total of 238,900 shares. Based on an average trading volume of 64,300 shares, the short-interest ratio is presently 4.0 days. Approximately 4.8% of the shares of the stock are sold short. View BioSpecifics Technologies' Current Options Chain.

Who are some of BioSpecifics Technologies' key competitors?

What other stocks do shareholders of BioSpecifics Technologies own?

Who are BioSpecifics Technologies' key executives?

BioSpecifics Technologies' management team includes the folowing people:
  • Dr. Ronald Law J.D., Ph.D., Interim Principal Exec. Officer (Age 66)
  • Mr. Patrick M. Caldwell, Interim Principal Financial Officer (Age 57)
  • Carl A. Valenstein, Corp. Sec.

Who are BioSpecifics Technologies' major shareholders?

BioSpecifics Technologies' stock is owned by many different of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (7.73%), BlackRock Inc. (5.88%), Rice Hall James & Associates LLC (4.86%), Vanguard Group Inc. (3.80%), Allianz Asset Management GmbH (1.56%) and AQR Capital Management LLC (1.55%). Company insiders that own BioSpecifics Technologies stock include Jennifer M Chao, Mark N Wegman, Of Edwin H Wegman Estate, Patrick M Caldwell, Paul Gitman, Thomas Wegman and Toby Wegman. View Institutional Ownership Trends for BioSpecifics Technologies.

Which institutional investors are selling BioSpecifics Technologies stock?

BSTC stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Clark Capital Management Group Inc., Renaissance Technologies LLC, Eagle Asset Management Inc., Invesco Ltd., Prudential Financial Inc., THB Asset Management and Bank of Montreal Can. Company insiders that have sold BioSpecifics Technologies company stock in the last year include Jennifer M Chao, Mark N Wegman, Of Edwin H Wegman Estate, Patrick M Caldwell, Paul Gitman and Toby Wegman. View Insider Buying and Selling for BioSpecifics Technologies.

Which institutional investors are buying BioSpecifics Technologies stock?

BSTC stock was purchased by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, AQR Capital Management LLC, Roubaix Capital LLC, Allianz Asset Management GmbH, Rice Hall James & Associates LLC, Wedge Capital Management L L P NC, BlackRock Inc. and Wells Fargo & Company MN. View Insider Buying and Selling for BioSpecifics Technologies.

How do I buy shares of BioSpecifics Technologies?

Shares of BSTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is BioSpecifics Technologies' stock price today?

One share of BSTC stock can currently be purchased for approximately $58.17.

How big of a company is BioSpecifics Technologies?

BioSpecifics Technologies has a market capitalization of $426.39 million and generates $32.96 million in revenue each year. The biopharmaceutical company earns $20.05 million in net income (profit) each year or $2.73 on an earnings per share basis. BioSpecifics Technologies employs 6 workers across the globe.View Additional Information About BioSpecifics Technologies.

What is BioSpecifics Technologies' official website?

The official website for BioSpecifics Technologies is http://www.biospecifics.com/.

How can I contact BioSpecifics Technologies?

BioSpecifics Technologies' mailing address is 35 Wilbur Street, Lynbrook NY, 11563. The biopharmaceutical company can be reached via phone at 516-593-7000 or via email at [email protected]


MarketBeat Community Rating for BioSpecifics Technologies (NASDAQ BSTC)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  243 (Vote Outperform)
Underperform Votes:  193 (Vote Underperform)
Total Votes:  436
MarketBeat's community ratings are surveys of what our community members think about BioSpecifics Technologies and other stocks. Vote "Outperform" if you believe BSTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BSTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel